Neuren Pharmaceuticals Limited

OTCPK:NURP.F Stock Report

Market Cap: US$1.0b

Neuren Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:NURP.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Aug 24BuyUS$66,879Joe BasileIndividual6,406US$10.44
17 Jul 24BuyUS$88,856,119Milford Asset Management, LTDCompany8,499,600US$10.45
17 Jul 24SellUS$88,536,417Milford Asset Management, LTDCompany9,003,256US$9.83
11 Jun 24BuyUS$64,277Joe BasileIndividual5,000US$12.86

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NURP.F?
Owner TypeNumber of SharesOwnership Percentage
Public Companies404,0720.316%
Individual Insiders4,235,3313.31%
Private Companies12,359,0129.67%
Institutions22,754,02517.8%
General Public88,063,23668.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 31.04% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.96%
The Vanguard Group, Inc.
6,339,022US$50.9m23.5%no data
4.74%
Milford Asset Management, LTD
6,058,321US$48.7m-7.68%0.95%
3.23%
Cameron Richard Pty Limited
4,123,084US$33.1m0%no data
2.06%
Stuart Andrew Pty. Ltd.
2,633,787US$21.2m0%no data
1.98%
Wilson Asset Management (International) Pty Ltd.
2,528,800US$20.3m0%0.63%
1.95%
Norges Bank Investment Management
2,486,288US$20.0m0%no data
1.89%
Trevor Scott
2,414,784US$19.4m0%no data
1.8%
BlackRock, Inc.
2,295,022US$18.4m3.36%no data
1.46%
Smithley Super Pty. Limited
1,870,000US$15.0m0%no data
1.38%
Linwierik Super Pty. Limited
1,761,385US$14.1m0%no data
0.69%
BetaShares Capital Limited
879,384US$7.1m3.02%0.04%
0.59%
First Colby Co Pty Ltd
750,000US$6.0m0%no data
0.59%
Mjhft Pty Ltd
750,000US$6.0m0%no data
0.53%
Robin Congreve
671,637US$5.4m0%no data
0.41%
State Street Global Advisors, Inc.
521,849US$4.2m-0.38%no data
0.38%
Goldman Sachs Asset Management, L.P.
481,489US$3.9m369%no data
0.37%
Emancipayte Pty ltd
470,756US$3.8m0%no data
0.33%
Netwealth Investments Ltd.
421,309US$3.4m0%0.04%
0.32%
He Zhao
405,000US$3.3m0%no data
0.32%
Pfizer Inc.
404,072US$3.2m0%no data
0.31%
Jonathan Pilcher
398,207US$3.2m0%no data
0.31%
Jupiter Fund Management Plc
396,906US$3.2m0%0.01%
0.21%
Patrick Donald Davies
264,634US$2.1m0%no data
0.16%
Charles Schwab Investment Management, Inc.
201,087US$1.6m0%no data
0.12%
Nordea Investment Management, AB
149,724US$1.2m0.01%no data